Spyre Therapeutics (SYRE) & Its Peers Critical Review

Spyre Therapeutics (NASDAQ:SYRE) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Spyre Therapeutics to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.

Risk & Volatility

Spyre Therapeutics has a beta of 3.24, indicating that its stock price is 224% more volatile than the S&P 500. Comparatively, Spyre Therapeutics’ competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Earnings and Valuation

This table compares Spyre Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spyre Therapeutics	$890,000.00	-$155.20 million	-38.13
Spyre Therapeutics Competitors	$702.95 million	$10.43 million	-15.13

Spyre Therapeutics’ competitors have higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Spyre Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1	1	13	2	2.94
Spyre Therapeutics Competitors	9858	15137	45528	1590	2.54

Spyre Therapeutics presently has a consensus price target of $110.53, suggesting a potential upside of 5.79%. As a group, “Biotechnology” companies have a potential upside of 99.99%. Given Spyre Therapeutics’ competitors higher possible upside, analysts plainly believe Spyre Therapeutics has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Spyre Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-35.97%	-27.67%
Spyre Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Summary

Spyre Therapeutics beats its competitors on 9 of the 13 factors compared.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.